Biogen Inc (BIIB)
221.69
-1.18
(-0.53%)
USD |
NASDAQ |
May 10, 16:00
221.69
0.00 (0.00%)
After-Hours: 18:34
Biogen Price to Book Value: 2.122 for May 10, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 2.133 |
| May 08, 2024 | 2.103 |
| May 07, 2024 | 2.095 |
| May 06, 2024 | 2.119 |
| May 03, 2024 | 2.082 |
| May 02, 2024 | 2.043 |
| May 01, 2024 | 2.068 |
| April 30, 2024 | 2.056 |
| April 29, 2024 | 2.062 |
| April 26, 2024 | 1.999 |
| April 25, 2024 | 1.938 |
| April 24, 2024 | 1.933 |
| April 23, 2024 | 1.849 |
| April 22, 2024 | 1.858 |
| April 19, 2024 | 1.850 |
| April 18, 2024 | 1.813 |
| April 17, 2024 | 1.829 |
| April 16, 2024 | 1.858 |
| April 15, 2024 | 1.873 |
| April 12, 2024 | 1.886 |
| April 11, 2024 | 1.939 |
| April 10, 2024 | 1.918 |
| April 09, 2024 | 1.966 |
| April 08, 2024 | 1.951 |
| April 05, 2024 | 1.940 |
| Date | Value |
|---|---|
| April 04, 2024 | 1.954 |
| April 03, 2024 | 1.964 |
| April 02, 2024 | 1.976 |
| April 01, 2024 | 2.045 |
| March 31, 2024 | |
| March 28, 2024 | 2.118 |
| March 27, 2024 | 2.125 |
| March 26, 2024 | 2.082 |
| March 25, 2024 | 2.128 |
| March 22, 2024 | 2.142 |
| March 21, 2024 | 2.168 |
| March 20, 2024 | 2.143 |
| March 19, 2024 | 2.147 |
| March 18, 2024 | 2.155 |
| March 15, 2024 | 2.154 |
| March 14, 2024 | 2.157 |
| March 13, 2024 | 2.225 |
| March 12, 2024 | 2.233 |
| March 11, 2024 | 2.260 |
| March 08, 2024 | 2.193 |
| March 07, 2024 | 2.155 |
| March 06, 2024 | 2.137 |
| March 05, 2024 | 2.134 |
| March 04, 2024 | 2.171 |
| March 01, 2024 | 2.170 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
1.813
Minimum
Apr 18 2024
5.845
Maximum
Jun 10 2021
3.313
Average
3.276
Median
Price to Book Value Benchmarks
| Eli Lilly and Co | 56.39 |
| Bristol-Myers Squibb Co | 5.523 |
| Gilead Sciences Inc | 4.687 |
| AbbVie Inc | 35.45 |
| Sage Therapeutics Inc | 1.014 |
Price to Book Value Related Metrics
| PE Ratio | 27.68 |
| PS Ratio | 3.339 |
| Price to Free Cash Flow | 25.12 |
| Price | 221.69 |
| Earnings Yield | 3.61% |
| Market Cap | 32.28B |
| Operating PE Ratio | 17.13 |
| Normalized PE Ratio | 20.41 |